These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 22975686

  • 1. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.
    Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ.
    Cell Signal; 2013 Jan; 25(1):106-12. PubMed ID: 22975686
    [Abstract] [Full Text] [Related]

  • 2. Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.
    Murray MY, Zaitseva L, Auger MJ, Craig JI, MacEwan DJ, Rushworth SA, Bowles KM.
    Cell Cycle; 2015 Jan; 14(14):2367-75. PubMed ID: 25565020
    [Abstract] [Full Text] [Related]

  • 3. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
    Kraus J, Kraus M, Liu N, Besse L, Bader J, Geurink PP, de Bruin G, Kisselev AF, Overkleeft H, Driessen C.
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
    [Abstract] [Full Text] [Related]

  • 4. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.
    Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ.
    Blood; 2014 Feb 20; 123(8):1229-38. PubMed ID: 24307721
    [Abstract] [Full Text] [Related]

  • 5. Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.
    Wang X, Fei Y, Liu X, Zhang T, Li W, Jia X, Liu X, Qiu L, Qian Z, Zhou S, Ren X, Zhai Q, Meng B, Li L, Zhang H.
    Aging (Albany NY); 2021 Sep 10; 13(17):21102-21121. PubMed ID: 34508613
    [Abstract] [Full Text] [Related]

  • 6. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
    Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC.
    Blood; 2009 Jul 30; 114(5):1046-52. PubMed ID: 19436050
    [Abstract] [Full Text] [Related]

  • 7. [Effect of PCI-32765 and bortezomib on proliferation and apoptosis of B-cell tumor cell lines and its mechanisms].
    Deng Y, Tao SD, Zhang X, He ZM, Chen Y, Deng ZK, Li YY, Yu L.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct 30; 21(5):1178-82. PubMed ID: 24156429
    [Abstract] [Full Text] [Related]

  • 8. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.
    Du HF, Yu LJ, Meng YF, Lv HY, Meng J, Song XN, Zhang JQ.
    Leuk Lymphoma; 2013 Mar 30; 54(3):607-18. PubMed ID: 22889356
    [Abstract] [Full Text] [Related]

  • 9. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
    Dasmahapatra G, Patel H, Dent P, Fisher RI, Friedberg J, Grant S.
    Br J Haematol; 2013 Apr 30; 161(1):43-56. PubMed ID: 23360303
    [Abstract] [Full Text] [Related]

  • 10. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.
    Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S, Aggarwal BB.
    Blood; 2007 Mar 15; 109(6):2293-302. PubMed ID: 17164350
    [Abstract] [Full Text] [Related]

  • 11. Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-κB and STAT3.
    Ma J, Gong W, Liu S, Li Q, Guo M, Wang J, Wang S, Chen N, Wang Y, Liu Q, Zhao H.
    Tumour Biol; 2018 Jan 15; 40(1):1010428317731369. PubMed ID: 29320977
    [Abstract] [Full Text] [Related]

  • 12. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.
    Ding N, Li X, Shi Y, Ping L, Wu L, Fu K, Feng L, Zheng X, Song Y, Pan Z, Zhu J.
    Oncotarget; 2015 Jun 20; 6(17):15122-36. PubMed ID: 25944695
    [Abstract] [Full Text] [Related]

  • 13. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
    Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, Neeser J, Mikail A, Adams J, Sjak-Shie N, Vescio RA, Berenson JR.
    Clin Cancer Res; 2003 Mar 20; 9(3):1136-44. PubMed ID: 12631619
    [Abstract] [Full Text] [Related]

  • 14. Bortezomib induces different apoptotic rates in B-CLL cells according to IgVH and BCL-6 mutations.
    Jantus-Lewintre E, Sarsotti E, Terol MJ, Benet I, García-Conde J.
    Clin Transl Oncol; 2006 Nov 20; 8(11):805-11. PubMed ID: 17134969
    [Abstract] [Full Text] [Related]

  • 15. In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
    Schmidt-Hieber M, Dabrowski R, Weimann A, Aicher B, Lohneis P, Busse A, Thiel E, Blau IW.
    Invest New Drugs; 2012 Apr 20; 30(2):480-9. PubMed ID: 21080211
    [Abstract] [Full Text] [Related]

  • 16. Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.
    Bu R, Hussain AR, Al-Obaisi KA, Ahmed M, Uddin S, Al-Kuraya KS.
    Leuk Lymphoma; 2014 Feb 20; 55(2):415-24. PubMed ID: 23697845
    [Abstract] [Full Text] [Related]

  • 17. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
    Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, Richardson P, Anderson KC.
    Clin Cancer Res; 2011 Aug 15; 17(16):5311-21. PubMed ID: 21724551
    [Abstract] [Full Text] [Related]

  • 18. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
    Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J, Mauro L, Prachand S, Miller R, Gordon LI, Evens AM.
    Clin Cancer Res; 2009 May 15; 15(10):3354-65. PubMed ID: 19417023
    [Abstract] [Full Text] [Related]

  • 19. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D, Li G, Podar K, Hideshima T, Neri P, He D, Mitsiades N, Richardson P, Chang Y, Schindler J, Carver B, Anderson KC.
    Cancer Res; 2005 Sep 15; 65(18):8350-8. PubMed ID: 16166312
    [Abstract] [Full Text] [Related]

  • 20. Ibrutinib in B-cell Lymphomas.
    Maddocks K, Blum KA.
    Curr Treat Options Oncol; 2014 Jun 15; 15(2):226-37. PubMed ID: 24481980
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.